Recap ISPOR 2023: Our expertise in action
By Xcenda
We are proud of our contributions to ISPOR 2023 in Boston. Kimberly Westrich shared valuable insights on comparative economic analysis. We showcased robust solutions that help biopharma partners enter the Canadian market. Our unparalleled research expertise was showcased through informative posters. We also offered innovative solutions for digital engagement with healthcare decision-makers.
Explore some of our expert contributions and related content that showcased our commitment to helping our biopharma partners accelerate product success and and advance health economics and outcomes research.
Explore some of our expert contributions and related content that showcased our commitment to helping our biopharma partners accelerate product success and and advance health economics and outcomes research.
ISPOR workshop
Addressing Heterogeneity in Comparative Economic Analysis in the Decentralized US Setting
Kimberly Westrich participated in this panel discussion that explored heterogeneity in comparative economic analyses, including a discussion of important sources relevant to the decentralized US setting, and examined comparative economic analysis supporting patient-centric decision-making. For more information on comparative economic analysisor to tap into Kimberly's expertise, contact us to start a conversation.
ISPOR 2023 poster presentations
View our groundbreaking research presented at ISPOR! Our research covers everything from the most critical challenges facing healthcare to showcasing groundbreaking solutions and the latest advancements in HEOR. We are incredibly proud to contribute to the conversation and share our findings.
Catch up on the latest edition of HTA Quarterly
Marking the 10th anniversary of HTA Quarterly, the editors reflect on the ever-changing face of market access, as biopharma companies, regulators, and payers unite in a common aim to improve outcomes for patients while directing funds to those products that offer the greatest value. We also look back at the first 3 years of Project Orbis, a collaborative program intended to standardize and streamline global approval of innovative oncology treatments, and consider the role of artificial intelligence in the future of HTA.
HTA Quarterly | Summer 2023
10 years of HTA Quarterly: Looking back to see how far we’ve come
On the 10th anniversary of HTA Quarterly, the editors take a look back at some of the articles published to date, identify key themes that resonate with our readers, and consider how shifts in the constantly changing world of market access have shaped article content.
HTA Quarterly | Summer 2023
Project Orbis: A three-year review
Project Orbis was launched by the FDA Oncology Center of Excellence to facilitate faster patient access to innovative cancer therapies in multiple countries. Leveraging a consortium of participating countries, Project Orbis aims for concurrent submission, review, and regulatory action for high-impact, clinically significant marketing applications among participating countries. This article provides an overview of the process and recent experiences of participating regulatory agencies, highlighting the benefits and challenges for stakeholders in the 3½ years since the first regulatory decision under Project Orbis took place in September 2019.
HTA Quarterly | Summer 2023
Reflections on an interview with a ghost
Is artificial intelligence (AI) set to take over the world? In this article, we reflect on an interview we conducted with one of the current AI tools, in which we explored its “knowledge” of and potential role in health technology assessment (HTA).
Innomar Strategies
Expand into the Canadian Market
Bringing a new therapy to market can be a long and complex process. We offer full end-to-end Canadian commercialization services tailored to meet your needs. With expert knowledge in the relevant service areas and a dedicated point of contact to guide you along the way, we make the experience seamless for you. By using our integrated network of solutions, we can help you to bring your products to the Canadian market successfully so they can reach the patients who need them.
FormularyDecisions®
Discover your perfect HCDM digital engagement package
Would you like to gain a competitive edge in engaging with healthcare decision makers (HCDMs)? Simply answer a few questions, and receive personalized recommendations straight to your inbox. With FormularyDecisions, you can impact and enhance your HCDM engagement strategy, staying ahead of the game. Don't miss out on this opportunity to unlock the full potential of digital HCDM engagement. Take our quiz today and elevate your HCDM engagement strategy to the next level!
